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Human leukocyte antigen (HLA)-DR15 is a haplotype associated with multiple sclerosis. It 
contains the two DRB* genes DRB1*1501 (DR2b) and DRB5*0101 (DR2a). The reported 
anchor motif of the corresponding HLA-DR molecules was determined in 1994 based 
on a small number of peptide ligands and binding assays. DR2a could display a set of 
peptides complementary to that presented by DR2b or, alternatively, a similar peptide 
repertoire but recognized in a different manner by T cells. It is known that DR2a and 
DR2b share some peptide ligands, although the degree of similarity of their associated 
peptidomes remains unclear. In addition, the contribution of each molecule to the global 
peptide repertoire presented by the HLA-DR15 haplotype has not been evaluated. 
We used mass spectrometry to analyze the peptide pools bound to DR2a and DR2b, 
identifying 169 and 555 unique peptide ligands of DR2a and DR2b, respectively. The 
analysis of these sets of peptides allowed the refinement of the corresponding binding 
motifs revealing novel anchor residues that had been overlooked in previous analyses. 
Moreover, the number of shared ligands between both molecules was low, indicating 
that DR2a and DR2b present complementary peptide repertoires to T cells. Finally, our 
analysis suggests that, quantitatively, both molecules contribute to the peptide repertoire 
presented by cells expressing the HLA-DR15 haplotype.
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inTrODUcTiOn
Human leukocyte antigen (HLA)-DP, -DQ, and -DR are membrane heterodimeric glycoproteins, 
composed by two chains, α and β, encoded in the class II region of the human major histocom-
patibility complex (MHC) or HLA. Thus, four different HLA-DP and HLA-DQ molecules are 
present in heterozygous cells, as each polymorphic α chain can interact with either polymorphic 
β chain. In the case of HLA-DR, the gene encoding the HLA-DRα subunit is dimorphic (and 
both forms are functionally equivalent). As such, only two different heterodimers are usually 
expressed. However, some haplotypes include two functional HLA-DRB genes, allowing the 
expression of four different molecules in heterozygous individuals, all of them carrying the same 
HLA-DRα chain. Specifically, the DR3, DR11, DR12, DR13, and DR14 haplotypes express DRB1 
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and DRB3; DR4, DR7, and DR9 express DRB1 and DRB4; and 
DR15 and DR16 express DRB1 and DRB5. The fact that some 
HLA haplotypes carry two different HLA-DRB genes suggests 
that this provide some advantages regarding the presentation of 
peptides derived from pathogens to CD4+ T cells.
It has been known for a long time that different HLA-DR mol-
ecules can present common peptides, indicating that HLA-DR 
molecules are to a certain level promiscuous. In fact, in the HLA 
class II, antigen processing pathway CLIP, derived from the 
invariant chain (Ii), must bind essentially all HLA-II molecules 
for a correct peptide selection. In addition, many other promiscu-
ous binders have been described so far (1–11).
Nevertheless, although the promiscuity of HLA-DR mole-
cules is accepted, the degree of overlap between different peptide 
repertoires has not been extensively addressed. In this regard, 
we compared the peptide repertoires of four HLA-DR allotypes 
differentially associated with rheumatoid arthritis and found a 
low degree of promiscuity in their bound peptidomes (12).
Human leukocyte antigen-DR15, a haplotype that expresses 
two functional HLA-DRB genes, is associated with multiple scle-
rosis (MS). MS is a chronic inflammatory disease of the central 
nervous system and is considered a T cell-mediated autoimmune 
disorder with a prevalence of 0.5–1.5 per 1,000 inhabitants in 
the northern hemisphere [reviewed in Ref. (13)]. The pathology 
is characterized by inflammation, demyelination, and axonal 
degeneration (14), and, as other autoimmune disease, its etiol-
ogy is not simple, involving multiple genetic and environmental 
factors. As said above, the HLA-DR15 haplotype is the strongest 
single genetic factor associated with MS with a reported odds 
ratio of 3.08 (15). This haplotype expresses DRB1 and DRB5 
genes, among which HLA-DRB1*15:01 (DR2b) and HLA-
DRB5*01:01 (DR2a) are the most prevalent alleles. The anchor 
motifs for DR2a and DR2b were described by several groups 
two decades ago (16, 17) based on a few peptides sequenced by 
Edman degradation and binding assays. Recently, a higher num-
ber of ligands of these allotypes have been described deriving 
from a low number of parental proteins, principally HLA-II and 
others proteins of the endogenous pathway (18). In addition, the 
Immuno Epitope Database and Analysis Resource (19) (http://
www.iedb.org/) reports binding data for several hundreds of 
peptides in relation to different HLA-DR allotypes, including 
DR2a and DR2b. However, the limited number of peptide eluted 
from these allotypes, which are the most relevant peptides pre-
sented in vivo, and peptides evaluated in binding assays means 
that the reported motifs may actually not include all potential 
anchor residues.
The co-expression of both DR2a and DR2b at the RNA level 
and on the cell surface has been demonstrated in different cell 
types (20). In that study, RNA levels were shown to be higher for 
DR2a, although protein expression on the cell surface seemed 
to be similar for both allotypes. Nevertheless, the contribution 
of the peptides presented by both HLA-DR molecules to the 
peptide repertoire presented by this haplotype and the degree of 
overlap between them remains unclear.
In this study, we have addressed three main questions: first, 
the fine-mapping of the anchor motifs of DR2a and DR2b by the 
identification of natural ligands bound to these allotypes; second, 
the degree of overlap of the peptide repertoires bound to these 
two HLA-DR molecules (DR2a and DR2b); and third, the con-
tribution of DR2a and DR2b to the peptide repertoire presented 
on the cell surface. To that end, we used liquid chromatography 
couple to tandem mass spectrometry (LC–MS/MS) to character-
ize the peptide repertoires associated with HLA-DRB1*15:01 
(555 unique peptides) and HLA-DRB5*01:01 (169 unique pep-
tides) from bare lymphocyte syndrome (BLS) transfected cells. 
This analysis allowed us to refine the binding motifs of these 
allotypes, identifying some novel anchor residues. The analysis 
of these peptide pools indicated that, although these molecules 
can share some peptides ligands, the overlap of both peptidomes 
was extremely low. Finally, our estimations indicate that both 
allotypes contribute similarly to the peptide repertoire presented 
by HLA-DR15 to CD4+ T cells.
MaTerials anD MeThODs
cell lines and antibodies
The BLS patient-derived B  cell line (BLS) transfected with the 
genes encoding the molecules DRB1*15:01 (BLS-DR2b) or 
DRB5*01:01 (BLS-DR2a) were kindly provided by G. Nepom and 
W. Kwok (University of Washington, Seattle, WA, USA) and were 
used as the source of the HLA-DR peptide ligands.
For the purification of the peptide pools associated with 
DRB1*15:01 or DRB5*01:01 the monoclonal antibody B8.11.2 
(IgG2b) was used. This antibody recognizes a DR framework 
structure present on all types of HLA-DR molecules (21, 22).
Purification of the hla-Dr-associated 
Peptide Pools
Peptides were purified as previously described (23, 24). About 
1 ×  109 cells were lysed in tris buffer (TB: 50  mM Tris/HCl 
(pH 7.6), 150 mM NaCl) with 1% Igepal-CA630 supplemented 
with protease inhibitors (cOmplete Protease Inhibitor Cocktail 
Tablet, Hoffman-La Roche, Basel, Switzerland) at 4°C for 2  h. 
Lysates were centrifuged for 10 min at 1,300 × g, and superna-
tants were ultra-centrifuged for 1 h at 100,000 × g. The soluble 
fraction was precleared using a Tris-blocked sepharose column 
(CNBr-activated sepharose, GE Healthcare Bio-Sciences AB, 
Sweden). The flow-through was incubated overnight at 4°C with 
B8.11.2-sepharose and washed as follows: first, with 50  ml of 
TB, 0.5% Igepal-CA630; then, with 200 ml of TB; and, finally, 
with 500 ml of Tris–HCl pH 7.6, 5 mM NaCl. HLA-DR–peptide 
complexes were eluted in 0.1% trifluoroacetic acid. Protein-
containing fractions were determined by the Bradford method, 
pooled and concentrated in a SpeedVac (Thermo Fisher scientific, 
Waltham, MA, USA). Peptides were purified by ultra-filtration 
in a Centricon-10 device (Millipore, Ireland, Ltd.). Retained 
material, containing HLA-DRα and β chains are shown in Figure 
S1 in Supplementary Material.
lc–Ms/Ms analysis
Samples were analyzed in a nano-LC ultra HPLC (Eksigent) 
coupled online with a 5,600 triple TOF mass spectrometer 
(AB Sciex) and equipped with a C18 chromXP trapping column 
3Scholz et al. HLA-DR Peptide Repertoires in MS
Frontiers in Immunology | www.frontiersin.org August 2017 | Volume 8 | Article 984
(350 µm × 0.5 mm, 3 µm, Eksigent) and a C18 chromXP column 
(75 µm × 150 mm, 3 µm, Eksigent). Solvent A and B were 0.1% 
formic acid and 0.1% formic acid in acetonitrile, respectively. 
Peptides were fractionated at a flow-rate of 300 nl/min at 40°C 
under gradient elution conditions, as follows: isocratic condi-
tions of 2% B for 1 min, a linear increase to 30% B in 181 min, a 
linear increase to 40% B in 23 min, a linear increase to 90% B in 
15 min, 90% B for 10 min, and back to initial conditions. Total 
runtime was 250  min. For blank injections, a shorter gradient 
was employed consisting of isocratic conditions of 5% B for 
1 min, a linear increase to 30% B in 109 min, a linear increase 
to 40% B in 10 min, a linear increase to 90% B in 5 min, 90% 
B for 5  min, and back to initial conditions. In this latter case, 
total runtime was 150 min. Each acquisition cycle comprised a 
survey scan (350–1,250 m/z) of 250 ms and up to of 25 MS/MS 
scans (100–1,500 m/z) of 100 ms. The HPLC and the mass spec-
trometer were, respectively, controlled with Eksigent Control 
(version 3.12, Eksigent) and Analyst TF (version 1.7, Eksigent). 
Total ion chromatogram of a blank and the samples and frag-
mentation spectra of two peptides are shown in Figure S2 in 
Supplementary Material. The MS/MS data have been deposited 
to the ProteomeXchange Consortium via the PRIDE partner 
repository (25) with the dataset identifier PXD006534.
Ms/Ms ion search and Peptide 
identification
Raw MS/MS data were converted to mgf files with Peakview 1.2 
(AB SCiex) and searched against a concatenated target-decoy 
database containing the 88,669 Uniprot entries of the Homo 
sapiens complete proteome set (as of March 2015) and their cor-
responding reverse sequences. The mgf file corresponding to the 
DR2b fraction was recalibrated with Protein Pilot (version 4.5, 
AB Sciex) before the search. MASCOT (Matrix Science, version 
2.5) was used as search engine with the following parameters: 
no enzyme, MS tolerance of 15  ppm, MS/MS tolerance of 
0.025 Da and protein N-terminal acetylation, pyroglutamic acid 
formation from glutamine, and methionine oxidation as variable 
modifications. Estimation of the false discovery rate (FDR) was 
carried out by decoy hit counting as previously described (26). 
Results were filtered at a FDR <5% at the peptide level.
identification of the Peptide-Binding core
All the peptides associated with DR2a or DR2b were analyzed 
with NetMHCIIpan 3.1 Software (27) to predict the binding 
core of each peptide. After the elimination of the redundant 
cores in nested sets, the remaining 9-mer cores were analyzed 
as previously described (28, 29). Preferences in residue usage 
were determined by comparing the observed frequency of each 
amino acid at each peptide position (fobs) with the frequency 
of the same amino acid in the database (fexp), named as 
deviation from mean in proteome (DMP) using a binomial test 
with Bonferroni’s correction. P-values <0.05 were considered 
statistically significant. Residues with a statistically significant 
increase after Bonferroni correction and a DMP value >2.5 were 
considered to be the main anchor residues. Secondary residues 
were those with a DMP value >1.5.
Modeling of the Peptide–hla-Dr 
interaction
Modeling of complexes between HLA-DR2a and HLA-DR2b 
and the different peptides was performed using a simulation 
protocol detailed elsewhere (12, 30). The binding score delivered 
by this procedure can be used to estimate the relative binding 
affinity of different peptides for the HLA molecules.
Binding assays
The experimental affinity of different peptides to HLA-DR 
molecules was determined as previously described (31). 
Briefly, recombinant DR2b (DRA1*01:01/DRB1*15:01) and 
DR2a (DRA1*01:01/DRB5*01:01) proteins were used for 
peptide-binding assays. Increasing concentrations of each non- 
biotinylated test peptide were incubated in competition with 
1  µM of the biotinylated GAD555-567 peptide (NLIRV-
VSSNRAAT, modified from NFFRMVISNPAAT to bind to 
DRB1*15:01 and DRB5*01:01 in a single unambiguous register) 
in wells coated with HLA-DR2a or HLA-DR2b. After washing, 
residual biotinylated reference peptide was labeled using euro-
pium conjugated streptavidin (Perkin Elmer) and quantified 
using a Victor3 D time resolved fluorometer (Perkin Elmer). 
Peptide-binding curves were simulated by non-linear regres-
sion with Prism Software (version 4.03, GraphPad Software 
Inc.) using a sigmoidal dose–response curve. IC50 binding 
values were calculated from the resulting curves as the peptide 
concentration needed for 50% inhibition of reference peptide 
binding. Equivalent amounts of purified HLA-DR protein were 
plated on each plate, but similar amounts of total protein can 
have different levels of activity. Thus, different preparations 
of protein frequently give different levels of maximum counts 
(presumably based on differences in purity and the proportion 
of the protein that is functional). Indeed differences between 
different preparations of the same HLA-DR protein can be 
observed. However, the observed IC50 values do not vary 
based on the maximum number of counts, probably because 
the labeled and unlabeled peptides are still competing for an 
equal number of binding sites.
resUlTs
characterization of the Peptide 
repertoires Bound to Dr2a and Dr2b 
Molecules
BLS-DR2a and BLS-DR2b cells were used as the source of the 
peptide–HLA-DR complexes. After purification by immunoaf-
finity chromatography, the trimeric complexes were denatured 
under acidic conditions and their associated peptides purified 
by ultra-filtration. The resulting peptide mixtures were analyzed 
by LC–MS/MS and peptide identification was carried out using 
Mascot as search engine. Peptides with a length of 11 amino acids 
or longer were considered for the analysis. A total of 177 and 
560 peptide ligands were identified from the DR2a and DR2b 
molecules, respectively. Peptides derived from some heterogene-
ous nuclear ribonucleoproteins were considered as background 
FigUre 1 | Peptide size distribution of the peptides sequenced from the 
different human leukocyte antigen-DR allotypes. (a) Groups of 100 Da  
were selected. Values shown are the percentage of peptides in each group. 
(B) Values shown are the percentage of peptides with different amino acid 
number.
FigUre 2 | Major cell location of the parental proteins of the peptides 
sequenced from the different human leukocyte antigen-DR molecules.  
(a) Values shown are the percentage of proteins for each cellular location.  
M, membrane; V, vesicular compartments; ER, endoplasmic reticulum;  
G, Golgi apparatus; S, secreted; C, cytosol; N, nucleus; Mit, mitochondria; 
ND, not determined. (B) Values shown are the percentage of proteins in each 
cellular pathway. Endocytic pathway comprises M, V, ER, G, and S. 
Endogenous pathway includes C, N, and M.
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contaminants on the basis of their particular features (their 
sequences were notably rich in Gly and Pro) and of our previ-
ous observations [similar peptides had been found in previous 
analysis of other unrelated HLA-II and HLA-I molecules (32)]. 
Thus, a final list of 169 unique peptides for DR2a and 555 unique 
peptides for DR2b were considered. The lists of these peptides 
and the corresponding parental proteins are shown in Tables S1 
and S2 in Supplementary Material.
The size distribution of the peptide ligands sequenced from 
the DR2 allotypes followed a normal distribution with an average 
molecular weight of 1,977.9 and 1,761.0 Da (Figure 1A) and a 
length of 17.6 and 15.9 residues for DR2a and DR2b, respectively 
(Figure 1B).
Most of the HLA-II ligands were peptides derived from pro-
teins located in the endocytic pathway, although some peptides 
came from cytosolic or nuclear proteins. To test if the DR2a- 
and DR2b-derived peptidomes were canonical regarding the 
subcellular location of their source proteins, we analyzed this 
parameter and found that most of them were located in vesicu-
lar compartments (Figure 2A). The fraction of parental proteins 
of the HLA-DR ligands located in the endocytic pathway was 
similar for DR2a (66.2%) and DR2b (68.1%) (Figure 2B). These 
observations confirmed that most of the peptides identified 
correspond to bona fide HLA-DR ligands.
refinement of the hla-DrB1*15:01  
and hla-DrB5*01:01 Binding Motifs
The HLA-DRB1*15:01 and HLA-DRB5*01:01 binding motifs 
were described years ago (16, 17). The described motif for 
binding to DR2a included bulky hydrophobic residues at the P1 
core position, Val, Ile, Met, or Gln at P4 and positively charged 
residues at P8 or P9. For DR2b, aliphatic residues (Leu, Val, or 
Ile) were preferred to Phe or Tyr at P1 and Met, Ile, Val, or Phe 
were favored at P4 and P7. Importantly, these anchor motifs were 
based only on the sequences of a limited number of peptides 
eluted from these allotypes and a few binding assays with selected 
peptides. It would not be unlikely that some anchor residues 
were not detected as part of the binding motif. Thus, in order 
to more robustly characterize the binding preferences of DR2a 
and DR2b, we identified the theoretical cores and calculated the 
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binding affinity with NetMHCIIpan 3.1 Server (27). To this end, 
each peptide was assayed against its corresponding HLA-DR 
allotype. If the same binding core was obtained for different 
peptides belonging to a nested set, this was considered only once 
in the analysis. As a result, 89 unique cores for DR2a and 270 for 
DR2b were considered. As shown in Figure 3, the anchor motifs 
described for each allotype were roughly similar to those reported 
previously. However, some differences could be observed. Thus, 
in the case of DR2a, the main anchor positions were P1, P4, P6, 
and P9. At P1, the preferred residues were Phe, Tyr, and Ile, and 
at P4 the only amino acid significantly overrepresented after 
the Bonferroni’s correction was Ala, which was not included 
in the previously defined motif. At P6, Pro, Ala, and Ser were 
favored. Finally, in P9, Lys and Arg were clearly the most frequent 
residues. In DR2b, P1, P4, P6, and P9 were also the main anchor 
residues. In P1, Ile and Val were the most favored amino acids. 
In P4, large aromatic residues Tyr and Phe were selected, while 
in P6 the polar amino acids Asn and Ser were preferred. Finally, 
the frequencies of Val were increased in P9 (Figure 3).
low similarity of the Peptide repertoires 
associated with Dr2a and Dr2b
Since the peptide-binding motifs of DR2a and DR2b showed 
some common features, we set out to analyze the degree of 
overlap of the two peptide pools. In our dataset, only 13 peptides 
were identified from both allotypes (7.7% for DR2a and 2.3% 
for DR2b) (Table 1). It is worth noting that both allotypes, and 
specially DR2a, displayed a large number of peptides derived 
from Ii, including six shared peptides derived from Ii. If these 
ligands were not included in the analysis, only seven peptides 
(4.1% for DR2a and 1.3% for DR2b) would be shared by both 
HLA-DR molecules.
We recently sequenced about 200 HLA-II-bound peptides 
from the DR2-homozygous B  cell lymphoblastoid cell line 
(B-LCL) MGAR (12). Among those, 22 peptides, grouped in 
15 nested sets, were also identified in this work, including 8 pep-
tides (6 nested sets) associated with DR2a and 14 (9 nested sets) 
with DR2b (Table 2). Remarkably, not a single peptide was found 
in the three repertoires confirming the low degree of overlap in 
the peptide repertoires associated with DR2a and DR2b.
contribution of hla-DrB1*15:01 and 
hla-DrB5*01:01 to the repertoire of  
hla-Dr15
To analyze the contribution of the peptides eluted from DR2a 
and DR2b to the global peptidome presented by the haplotype 
DR15, we analyzed the peptide pool sequenced in the present 
work and in a previous report from the B-LCL, MGAR (12). 
First, we used the NetMHCIIpan 3.1 Software to identify the 
putative MHC-interacting peptide cores. This program com-
putes a theoretical binding affinity for each peptide. Using this 
approach, 88.8% of the peptides identified from BLS-DR2a cells 
presented higher affinity for DR2a than for DR2b (Table S3 in 
Supplementary Material). By contrast, only 43.4% of the natural 
DR2b ligands showed higher affinity for DR2b than for DR2a 
(Table S4 in Supplementary Material). In an attempt to tackle 
this apparent contradiction, we carried out a second approach 
using the refined binding motif described in the present work. 
A new score was generated for all the 9-mer cores by adding 
up the DMPs values obtained of each residue at each position. 
With this new scoring scheme, 85.8% of the peptides sequenced 
from DR2a had a higher affinity for DR2a than for DR2b (Table 
S5 in Supplementary Material). Most importantly, the fraction 
of peptides with a higher affinity for DR2b in the peptide pool 
obtained from this allotype increased from 43.4 to 86.1% (Table 
S6 in Supplementary Material). These data indicate that the 
empirical information obtained from the characterization of 
MHC-bound peptidomes is complementary to that provided 
by bioinformatics tools such as NetMHC2pan 3.1. Moreover, as 
shown here, it can improve the prediction of binding affinities 
and contribute to define more accurate anchor motifs.
This same approach was conducted with the peptide pool 
isolated from the MGAR cell line. Using that dataset and the here 
defined score, we estimate that 51.1% of the peptides displayed 
by DR15 are presented by DR2a and the remaining 48.9% by 
DR2b (Table S7 in Supplementary Material). Therefore, our data 
suggest that, in the DR15 haplotype, the contribution of both 
HLA-DR molecules to the conformation of the HLA-DR15 
peptide repertoire is similar, at least in quantitative terms.
Binding assay to hla-Dr Molecules
To gain insight into the molecular features that govern the 
interaction of DR15 with its peptide ligands we considered the 
8 and 14 peptides associated, respectively, with DR2a and DR2b 
that we described in a previous report (12) (Table 2).
We calculated their theoretical binding affinities with 
NetMHCIIpan 3.1. All the sequences tested showed a high 
affinity (IC50 < 1,000 nM) except the peptide TPKIQVYSRHP, 
derived from β2-microglobulin, which probably is not a real 
ligand, but a contaminant. Of note, all the peptides presented 
higher affinity for the allotype from which they were sequenced, 
with the exceptions of the nested set LEEFGRFASFEAQG(A) 
and the peptide TPKIQVYSRHP, which were identified from 
the BLS-DR2b cell line but showed a higher theoretical affinity 
for DR2a (Table 2). Interestingly, when the theoretical affinity 
was computed with the empirical scoring scheme generated in 
the present work, all the sequences presented a higher affinity 
for the HLA-DR molecule from which they derived except the 
peptide NPPDIVVQPGHIR, sequenced from DR2a and with a 
theoretical higher affinity for DR2b (Table 2).
To get an experimental measure of the binding affinities of 
some natural ligands of DR15, we synthesized the peptides ELE 
ELRAEQQRLKSQDL, QTKEFQVLKSLGKLAMG, and SQA E 
FE KAAEEVRHL (sequenced from BLS-DR2a and the homozy-
gous B-LCL MGAR) and the peptides LEEF GRFASFEAQG, LPS 
EKAIFLFVDKTVPQS, and QKKEIHLYQTFVVQ (seq uenced 
from BLS-DR2b and MGAR). These were used in a binding 
assay to determine their binding affinity to DR2a and DR2b. 
The three peptides sequenced from DR2a showed a high affinity 
for DR2a ranging from 0.08 to 5.8 µM, while they failed to bind 
to DR2b (Figure  4A). The peptide LPSEKAIFLFVDKTVPQS, 
identified from DR2b, bound to DR2b with an IC50 of 14.5 µM 
and non-detectable affinity for DR2a. Surprisingly, the other two 
FigUre 3 | Refined anchor motifs for DR2a and DR2b molecules. (a) Residue use among DR2a (white) and DR2b (black) natural ligands. For each of the peptide 
core positions (P), the percent frequency of each amino acid was calculated. Normalized values were calculated as the number of times that each relative frequency 
was increased or decreased relative to the mean frequency of the corresponding residue among human proteins (deviation from the mean in the proteome [DMP]). 
DMP values are presented as histograms. (B) DR2a and DR2b peptide-binding motifs. Residues with a statistically significant increase after Bonferroni correction 
(top) and a DMP value >2.5 were considered to be the main anchor residues. Secondary residues are also shown, which were those with a DMP value >1.5.
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TaBle 1 | Shared peptides between DR2a and DR2b.
# Protein Peptide
1 Cofilin-1 ASGVAVSDGVIKVFNDMKVR
2 Cofilin-1 ASGVAVSDGVIKVFNDMKVRK
3 Integrin beta NIQPIFAVTSRMVKTYE
4 Invariant chain KPPKPVSKMRMATPLLMQA
5 Invariant chain KPPKPVSKMRMATPLLMQALP
6 Invariant chain LPKPPKPVSKM
7 Invariant chain LPKPPKPVSKMRMATPLLMQAL
8 Invariant chain LPKPPKPVSKMRMATPLLMQALP
9 Invariant chain LPKPPKPVSKMRMATPLLMQALPM
10 Nuclease-sensitive element- 
binding protein 1
PPAENSSAPEAEQGGAE
11 Protein CutA PALLPVASRLLLLP
12 SWI/SNF complex subunit 
SMARCC2
PGTPLPPDPTAPSPGTVTPVPPPQ
13 SWI/SNF complex subunit 
SMARCC2
PTAPSPGTVTPVPPPQ
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BLS-DR2b-sequenced peptides failed to bind to both allotypes 
(Figure  4B). The failure of these two peptides (with the theo-
retical binding cores, FGRFASFEA and IHLYQTFVV) to bind 
to DR2b was unexpected since they matched the DR2b motif. 
This was especially evident for the latter sequence, as the peptide 
with a high affinity harbored a theoretical core (IFLFVDKTV) 
with very similar main anchor residues (P1: Ile vs. Ile; P4: Tyr vs. 
Phe; P6: Thr vs. Asp; and P9: Val vs. Val).
Modeling of Mhc–Peptide complexes
Computational models of the complexes of the putative cores 
obtained from the NetMHCIIpan 3.1 Server and some additional 
cores of these peptides with both DR2a and DR2b were made. 
The simulation protocol has been previously described (12, 30).
Table 2 shows the energetically most favored core for each 
peptide complexed with each molecule and the corresponding 
binding score (given as a Gibbs free energy). Energetically, all 
the peptides sequenced from DR2b would interact better with 
DR2b than with DR2a. The models of the peptides sequenced 
from DR2a indicated that four of six peptides theoretically 
interacted better with DR2a than with DR2b. The other two 
peptides bound energetically better to DR2b than to DR2a.
Figure  5 shows examples of the cores obtained from two 
peptides identified in cells expressing DR2a (FEKAAEEVR) 
and DR2b (IVIFQSKPE) complexed with both molecules. The 
rest of the peptides complexed with DR2a and DR2b are shown 
in Figure S3 in Supplementary Material. The models shown in 
Figure 5 indicated that the mutation G86V reduces significantly 
the cavity in DR2b, sterically decreasing the affinity for the 
large aromatic residues. In P4, the mutation R71A increases 
significantly the size of the pocket in DR2b, favoring the binding 
of large aromatic residues. Finally, in P9 the mutations D30Y, 
D37S (and to a lesser extent D11P) reduce greatly the affinity of 
the pocket for positively charged residues in DR2b, while at the 
same time the mutation Q9W reduces also the size of the cavity, 
thus explaining the preference of this pocket in DR2b for smaller 
apolar residues. The peptide IVIFQSKPE showed a higher affinity 
for DR2b (score of −150 kJ/mol) than for DR2a (−58 kJ/mol) 
(Figure 5). This is consistent, according to the previous analysis, 
with the positioning of residues Ile in P1 (more common in 
DR2b), Phe in P4 (good affinity for DR2b, too bulky for DR2a) 
and Glu in P9 (wrong charge for DR2a, less bad for DR2b). 
On the other side, the peptide FEKAAEEVR shows a higher affin-
ity for DR2a (−112 kJ/mol) than for DR2b (−82 kJ/mol). This is 
also consistent with the positioning of residues Phe in P1, Ala 
in P4, and Arg in P9, all of which with higher affinity for DR2a.
DiscUssiOn
The HLA is polygenic, containing several different HLA genes, 
which encode classical HLA molecules, which are highly poly-
morphic and show codominant expression. These features are 
relevant to the function of the proteins they encode, that is, the 
presentation on the cell surface of peptides derived from aber-
rant or non-self proteins to specific T lymphocytes. In the case of 
HLA-II heterodimers, both chains conform the peptide-binding 
site. Thus, the combination of two polymorphic α chains with 
two polymorphic β chains, as occurs in HLA-DP and -DQ pro-
teins, increases the theoretical capacity of peptide presentation. 
The fact that HLA-DRα is not polymorphic greatly reduces the 
diversity of the displayed peptide repertoire. However, in some 
haplotypes, this is compensated with the expression of two dif-
ferent HLA-DRB loci. The selection of these complex haplotypes 
may indicate that the presentation of different peptides derived 
from pathogens to CD4+ T  lymphocytes constitutes a selective 
advantage. In addition, the presence of two different functional 
genes could be the result of a gene duplication that is not a dis-
advantage (but not necessarily an advantage) and, thus, has not 
been removed from the genome.
Human leukocyte antigen-DR15 is one of the haplotypes 
which harbors two functional loci, DRB1 and DRB5 typically 
encoding the DRB1*15:01 and DRB5*01:01 allotypes. HLA-DR15 
is associated with MS, and several immunogenic peptides 
presented by these molecules have been reported. The anchor 
motifs of these molecules were described in 1994 considering 
the sequences of a few peptides bound to DR2a and DR2b and 
some binding assays (16, 17, 33). We have refined these motifs in 
the present work based on the peptides identified from the BLS 
cell line stably transfected with the corresponding genes. The 
resulting binding motifs are overall similar, although some clear 
differences emerged from our analysis. For instance, for DR2a, 
Ala appeared as the main anchor motif in the P4 core position, 
a feature that was not observed in previous reports (16, 17). 
A second major difference involved DR2b. In the formerly 
reported anchor motif, the main anchor positions were P1, 
P4, and P7. In our data, by contrast, these were P1, P4, P6, and 
P9. The P1 and P4 anchor positions were very similar to those 
described previously. In P6, which was not previously described 
as an anchor position, polar residues, principally Asn and Ser, 
were favored with our data. In P9, Val was the most preferred 
residue, but Ala and Leu were other favored residues. We did not 
find a clear preference for some residues in P7, which was defined 
as an anchor position. The peptide parental protein described 
here are more diverse than those described previously and locat-
ing in the endocytic compartment, what strongly suggests that 
TaBle 2 | Common peptides from MGAR and BLS-DR2a or BLS-DR2b.
PePTiDe seQUenceD FrOM netMhciiPan 3.1 Matrix of this paper BinDing  
[ic50 (nM)]
MODeling (Δg, kJ/mol)
Dr2a Dr2b Mgar cOre  
Dr2a
ic 50 (nM) 
Dr2a
cOre  
Dr2b
ic 50 (nM) 
Dr2b
core  
Dr2a
score 
Dr2a
core  
Dr2b
score 
Dr2b
Dr2a Dr2b cOrea Dr2a Dr2b
LEEFGRFASFEAQG X X FGRFASFEA 275.33 FGRFASFEA 500.20 FGRFASFEA 13.411 FGRFASFEA 16.571 >50 μM >50 μM FGRFASFEA −41 −55
LEEFGRFASFEAQGA X X
ADDGKIVIFQSKPEIQ X X IVIFQSKPE 564.48 IVIFQSKPE 213.78 IVIFQSKPE 15.037 IVIFQSKPE 24.163 ND ND IVIFQSKPE −58 −150
APGAGSLALFPGIRLE X X LALFPGIRL 148.05 LALFPGIRL 112.11 SLALFPGIR 13.674 LALFPGIRL 18.801 ND ND LALFPGIRL −50 −97
LPSEKAIFLFVDKTVPQ X X FLFVDKTVP 1,108.20 IFLFVDKTV 362.52 KAIFLFVDK 12.652 IFLFVDKTV 22.154 – 14.5 μM IFLFVDKTV −52 −86
LPSEKAIFLFVDKTVPQS X X
LVRVVVPYQGPSSDY X X VRVVVPYQG 1,365.31 VRVVVPYQG 460.01 VRVVVPYQG 13.268 VVPYQGPSS 22.408 ND ND VRVVVPYQG −35 −100
VVPYQGPSS −80 −114
NEQKLNRYPASSLVVVR X X LNRYPASSL 181.61 LNRYPASSL 150.87 RYPASSLVV 13.245 LNRYPASSL 20.546 ND ND LNRYPASSL −82 −94
QKKEIHLYQTFVVQ X X IHLYQTFVV 577.16 IHLYQTFVV 86.23 IHLYQTFVV 9.231 IHLYQTFVV 26.846 >50 μM >50 μM IHLYQTFVV −42 −102
QKKEIHLYQTFVVQL X X 9.231
QKKEIHLYQTFVVQLQDPR X X QTFVVQLQD 10.604
QKKEIHLYQTFVVQLQDPREP X X 10.604
QPGVLIQVYEGERAM X X IQVYEGERA 660.48 IQVYEGERA 487.63 LIQVYEGER 12.470 IQVYEGERA 27.822 ND ND IQVYEGERA −61 −123
TPKIQVYSRHP X X PKIQVYSRH 1,423.97 PKIQVYSRH 3,407.84 TPKIQVYSR 11.077 KIQVYSRHP 13.167 ND ND PKIQVYSRH −77 −100
ADIQTERAYQKQP X X IQTERAYQK 190.72 IQTERAYQK 3,028.33 IQTERAYQK 19.227 IQTERAYQK 17.163 ND ND IQTERAYQK −58 −117
ELEELRAEQQRLKSQD X X LRAEQQRLK 140.55 LRAEQQRLK 2,413.08 LRAEQQRLK 17.190 LRAEQQRLK 9.480 2.4 μM >50 μM LRAEQQRLK −116 −107
ELEELRAEQQRLKSQDL X X QQRLKSQDL 10.511
NPPDIVVQPGHIR X X IVVQPGHIR 131.27 IVVQPGHIR 1,690.71 IVVQPGHIR 16.488 IVVQPGHIR 19.347 ND ND IVVQPGHIR −47 −76
QTKEFQVLKSLGKLA X X FQVLKSLGK 5.89 FQVLKSLGK 62.71 FQVLKSLGK 21.571 FQVLKSLGK 13.238 0.08 μM >50 μM FQVLKSLGK −88 −56
QTKEFQVLKSLGKLAMG X X
SQAEFEKAAEEVRHL X X FEKAAEEVR 493.62 FEKAAEEVR 5,881.78 FEKAAEEVR 20.382 QAEFEKAAE 10.940 5.8 μM >50 μM FEKAAEEVR −112 −82
VAIVQAVSAHRHR X X IVQAVSAHR 4.87 IVQAVSAHR 35.95 IVQAVSAHR 20.445 IVQAVSAHR 18.858 ND ND IVQAVSAHR −154 −138
aFor the peptide LVRVVVPYQGPSSDY, the two cores obtained with NetMHCIIPan 3.1 and the score of this work are shown.
ND, not determined.
Bold indicates the DR molecule with the best score.
8
S
cholz et al.
H
LA
-D
R
 P
eptide R
epertoires in M
S
Frontiers in Im
m
unology | w
w
w
.frontiersin.org
A
ugust 2017 | Volum
e 8 | A
rticle 984
FigUre 4 | Experimental binding affinity of peptides sequenced from MGAR 
and (a) Binding to DR2a or (B) Binding to DR2b. Increased concentration of 
the peptides were incubated in wells coated with recombinant human 
leukocyte antigen (HLA)-DR2a or HLA-DR2b in competition with 1 µM 
biotinylated modified GAD555-567 peptide (NLIRVVSSNRAAT, modified from 
NFFRMVISNPAAT to bind to DRB1*15:01 and DRB5*01:01 in a single 
unambiguous register) to generate binding curves. After washing, residual 
biotinylated reference peptide was labeled using europium-conjugated 
streptavidin and quantified. The Y-axis depicts raw europium counts, which is 
proportional to the amount of residual biotinylated peptide that remains 
bound to HLA class II. White-filled symbols represent peptides eluted from 
DR2a. Black-filled symbols represent peptides eluted from DR2b.
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most of the peptides are bona fide HLA-DR ligands. Since these 
are the canonical anchor residues in most HLA-DR molecules 
and we used a larger set of peptides to fine-map the DR2b 
binding motif, we reckon that the here reported motif is more 
accurate. Several crystal structures demonstrated that these are, 
in fact, the residues that interact with the groove both in DR2b 
(34, 35) and DR2a (36, 37). Moreover, the residues preferred 
at P6 were polar or small as described previously for most 
HLA-DR molecules (38).
Interestingly, P8 showed an increased frequency of positively 
charged residues (Lys in DR2a and Lys, His and Arg in DR2b). 
In this regard, we made a similar observation in DRB1*01:01, 
DRB1*04:01, and DRB1*10:01 (12). On the whole, our data 
reflect that both DR2a and DR2b favored the binding of pep-
tides with basic residues at P8 and suggest that the preference of 
positively charged residues in this position may be an extended 
preference for many HLA-DR allotypes.
A relevant aspect that we also evaluated in this study is 
the promiscuity of peptide binding in HLA-II molecules. It is 
well-known that some peptides can bind to many HLA-DR 
molecules. In the case of HLA-DR15, the anchor motifs of DR2a 
and DR2b are different, both allotypes can accommodate similar 
or identical residues at major anchor positions. Thus, although 
with different prevalence, both molecules can accept aliphatic 
or aromatic residues in P1 and P4, polar residues in P6 and 
aliphatic and basic residues in P9. Nevertheless, our data show 
that, although some particular peptides can be presented by 
both molecules, the global degree of overlap is low. These data 
agree with our previous finding that, the overlap between the 
peptide repertoires associated with DRB1*01:01, DRB1*04:01, 
DRB1*10:01, and DR15 is low, even between the most similar 
DR1 and DR10 repertoires (12). Notably, in the here-reported 
datasets, the peptide overlap is even lower.
Among the peptides identified in this study, only 13 peptides 
were common to DR2a and DR2b. Six of them derived from 
the invariant chain, mirroring the high abundance of Ii-derived 
ligands in this cell line, a phenomenon particularly evident in 
DR2a. The seven remaining common peptides derived from 
five different proteins, two of them located in the plasma mem-
brane, two in the nucleus, and one in the cytosol. The three 
peptides derived from nuclear or cytosolic proteins presented a 
low theoretical affinity calculated either with NetMHCIIpan 3.1 
(Tables S3 and S4 in Supplementary Material) or with the matrix 
generated in this work (Tables S5 and S6 in Supplementary 
Material). Thus, we cannot discard that some of the sequenced 
peptides are contaminants. Nevertheless, this will not be the 
case for most of them as: (1) the anchor motif that we observe 
is similar to that described previously and (2) the subcellular 
locations of their parental proteins is the expected for the 
identified ligands. However, considering that background 
contaminants are more likely to be detected in both cell lines 
as they are allele independent, the actual overlap could be even 
lower than reported here.
The low degree of overlap suggests that, at least in the case 
of DR15, the existence of two DR alleles can increase the 
diversity of the peptide repertoire presented to T lymphocytes. 
More over, since some peptides can be presented in different 
registers, as demonstrated previously for the peptide spanning 
residues 86–105 of the myelin basic protein (37). In this case, the 
anchor residues were Phe1, Ile4, Thr6, and Thr9 for DR2a and 
Val1, Phe4, Asn6, and Thr for DR2b, which are favored or well-
accepted residues in the binding motifs described in this report. 
The presentation of the same peptide in different registers allows 
to increase the number of CD4+ T cells recognizing a particular 
antigenic peptide as different clones would recognize the differ-
ent registers of each peptides.
The modeled structures of the peptide ligands complexed 
with DR2a and DR2b can be rationalized in light of the anchor 
motifs obtained in this work. Thus, the binding motifs for both 
alleles show that selection is primarily done at the level of P1, 
P4, and P9. P1 binds preferentially large aromatic residues 
in DR2a and smaller aliphatic residues (preferentially Ile) 
in DR2b. P4 shows the opposite trend, with small aliphatic 
residues in DR2a and aromatic residues in DR2b. Finally, P9 
shows a preference for basic residues in DR2a and aliphatic 
residues in DR2b. These preferences can be broadly explained 
by the sequence differences between DR2a and DR2b. Thus, 
the dimorphism G86V explains the preference of each allotype 
in P1. As seen in Figure  3, P4 is a more restrictive position 
in DR2b than in DR2a, what can be structurally explained by 
FigUre 5 | Model structures of the peptides IVIFQSKPE (eluted from DR2b) and FEKAAEEVR (eluted from DR2a) complexed with DR2a or DR2b. Computed 
binding scores for IVIFQSKPE are −58 kJ/mol to DR2a and −150 kJ/mol to DR2b. Computed binding scores for FEKAAEEVR are −112 kJ/mol to DR2a and 
−82 kJ/mol to DR2b.
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the polymorphism R71A (Figure  5). P9 is more restrictive 
in DR2a than in DR2b, having preference for basic residues, 
what is explained by the presence of Asp30, Asp37, and Asp11. 
Although the conclusions of in  silico models are speculative, 
there are data enough in the literature that experimentally 
confirm our main conclusions. Specifically, the mutant G86V 
is a natural polymorphism present in some HLA-DR alleles. 
Thus, many of the most studied alleles contain Gly86, while 
DRB1*03:01 and DRB1*04:04 contain Val86. We analyzed the 
peptidomes bound to some HLA-DR molecules containing 
Gly86, as DRB1*01:01 (12, 24, 39) and all of them bind preferen-
tially peptides with aromatic residues in P1. HLA-DRB1*04:01 
present Gly86 while HLA-DRB1*04:02 and HLA-DRB1*04:04 
contain Val86. The binding motifs of these allotypes have been 
described using transfectants where the DRB4 gene was not 
expressed (40). DRB1*04:01 also binds principally Phe and Tyr, 
while the two molecules with Val86 prefer smaller aliphatic 
residues. Thus, these data confirm our pMHC computer-based 
models. Regarding the P4 anchor position, there are other 
polymorphisms in the residues affecting the corresponding 
pocket and there are few common DRB genes with Ala71. 
Nevertheless, some studied HLA-DR molecules contain Arg71, 
as DRB1*04:04, DRB1*08:01, DRB1*10:01, and all of them bind 
preferentially aliphatic residues in P4, in concordance with the 
residues found for DRB5*01:01 (which also contains Arg71) 
and in contrast with the clear preference for aromatic residues 
obtained for DRB1*15:01 (which contains Ala71). Finally, 
regarding the DRB residues proposed to affect the interaction 
with the P9 anchor residue, there are not common alleles 
carrying Asp in these positions. However, the conclusion that 
the preference for basic residues in P9 is due to the introduction 
of three negative charges (P11D, Y30D, and S37D) in DR2a is 
very likely, as indicated by the models.
In this work, we have used an LC–MS/MS-based peptidomic 
approach to refine the binding model of two HLA-DR allotypes 
associated with MS. To our knowledge, this is the first time that the 
peptide repertoires of two HLA-DR molecules belonging to the 
same haplotype are directly compared. In this context, our data 
indicate that the overlap in their bound peptidomes is very low. 
In addition, our data suggest that, quantitatively both molecules 
contribute to a similar extent to the configuration of the peptide 
pool displayed by HLA-DR15 on the cell surface. Finally, although 
the peptides sequenced here do not have special relevance to MS, 
as they do not come from known autoantigens, we propose that 
the analysis of peptide ligands eluted from HLA-DR molecules 
shows to be complementary to bioinformatics tools and can con-
tribute to improve the prediction of new T cell epitopes relevant 
for autoimmune diseases.
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FigUre s1 | SDS-PAGE gel of immunoprecipitated HLA-DR2a and -DR2b 
molecules. Peptide–HLA-DR complexes were eluted in acid medium and passed 
through a Centricon-10 device. The retained material was loaded on a 12% 
SDS-PAGE gel. Arrows show α and β HLA-DR chains.
FigUre s2 | Total ion chromatogram and fragmentation spectra of peptides 
sequenced from DR2a and DR2b molecules. Pages 1, 2, and 6 show the total 
ion chromatograms (TICs) of a blank, DR2a and DR2b samples, respectively. 
Pages 3 and 7 show the extracted ion chromatograms (XICs) of signals 
790.9301 (from DR2a) and 746.0306 (from DR2a), respectively. Page 4 shows 
the fragmentation spectrum of the peptide TPLLMQALPMGALPQ, and page 5 
shows the annotation of the corresponding fragments (black fonts correspond to 
the theoretical masses generated during the peptide fragmentation; red fonts 
correspond to the masses found in the fragmentation spectrum). Page 8 shows 
the fragmentation spectrum of the peptide GLQADLSSFKSQELNERNEA, and 
page 9 shows the annotation of the corresponding fragments (black fonts 
correspond to the theoretical masses generated during the peptide 
fragmentation; red fonts correspond to the masses found in the fragmentation 
spectrum).
FigUre s3 | Model structures of DR15 ligands complexed with DR2a and 
DR2b. The interactions of the identified binding cores from peptides sequenced 
from MGAR (DR15) and from BLS-DR2a or -DR2b and DR2a and DR2b were 
modeled. Figures show the graphical representation of the models most 
favorable energetically.
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